Resources
Vero is a kidney epithetical cell line derived from an African Green Monkey. Vero gets its name from a derivation of green kidney- Verda Reno. Verotoxin, a potent E.coli toxin that is involved in severe food poisoning and can cause kidney failure, was originally so-named (now known as shiga-like toxin) as it was first screened by its ability to kill vero cells.
Vero cell lines are used less frequently in biological studies than the more popular HeLa cell line, in part because this is a non-human cell line. However, Vero cell lineages are still widely used for screening purposes for bacterial toxins, viruses and for parasite studies. Since they are derived from normal kidney cells and not immortal cells like HeLa, Vero cells retain the attributes of normal cells, notably cell contact inhibition. So, once they reach confluence in the cell mono layer, they need to be passaged otherwise they will start to die off. In addition, Vero cells have been used in the development and validation of techniques such as super resolution microscopy.
The emergence of novel coronaviruses that have caused more lethal illnesses, namely SARS, MERS and COVID-19 has led to an increase into research of coronaviruses and for identifying antiviral strategies for COVID-19 in particular. Vero cell lines are one of a number of cell lines that are being used in a large number of these studies. Examples of these studies include evaluation of existing antiviral and other drugs for improved treatment within as short a time-frame as possible. It is often difficult to obtain robust data from the clinical cases directly given the many variables involved. For example, use of anti-viral treatments may have improved patient outcome if given at an early stage but not once complications developed further, or that the patient may have recovered regardless of being given a specific treatment. Therefore, effective research models are one important part of helping to determine what anti-viral treatments can be seen to have a statistically relevant impact and warrant further study.
Date: May 2020
Author: Dr Alan Mullan & Dr Aleksandra Marsh
Category: Application Note